T. Rowe Price Associates’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$92.8M Buy
1,934,261
+700,840
+57% +$30.7M 0.01% 627
2025
Q4
$47.7M Buy
1,233,421
+202,637
+20% +$7.73M 0.01% 830
2025
Q3
$36.4M Buy
1,030,784
+753,595
+272% +$27.3M ﹤0.01% 887
2025
Q2
$9.99M Buy
277,189
+7,726
+3% +$256K ﹤0.01% 1113
2025
Q1
$8.39M Buy
269,463
+23,016
+9% +$730K ﹤0.01% 1146
2024
Q4
$6.29M Sell
246,447
-39,852
-14% -$1.06M ﹤0.01% 1233
2024
Q3
$8.1M Buy
286,299
+15,847
+6% +$439K ﹤0.01% 1180
2024
Q2
$7.13M Buy
270,452
+8,722
+3% +$242K ﹤0.01% 1161
2024
Q1
$7.95M Sell
261,730
-1,106,424
-81% -$32.6M ﹤0.01% 1145
2023
Q4
$38.4M Sell
1,368,154
-622,848
-31% -$17.1M 0.01% 777
2023
Q3
$54M Sell
1,991,002
-303,414
-13% -$9.01M 0.01% 661
2023
Q2
$70.5M Sell
2,294,416
-181,531
-7% -$6.15M 0.01% 608
2023
Q1
$89.2M Sell
2,475,947
-28,585
-1% -$1.06M 0.01% 535
2022
Q4
$99M Buy
2,504,532
+161,722
+7% +$6.75M 0.02% 498
2022
Q3
$94.1M Sell
2,342,810
-9,732
-0.4% -$416K 0.02% 500
2022
Q2
$98.9M Buy
2,352,542
+91,343
+4% +$3.74M 0.01% 665
2022
Q1
$88.1M Sell
2,261,199
-16,360
-0.7% -$642K 0.01% 769
2021
Q4
$90.8M Buy
2,277,559
+80,823
+4% +$3.14M 0.01% 795
2021
Q3
$79.4M Sell
2,196,736
-3,117
-0.1% -$121K 0.01% 842
2021
Q2
$90.2M Sell
2,199,853
-154,365
-7% -$6.57M 0.01% 815
2021
Q1
$103M Sell
2,354,218
-854,937
-27% -$40.5M 0.01% 769
2020
Q4
$161M Sell
3,209,155
-5,021,895
-61% -$213M 0.02% 581
2020
Q3
$346M Buy
8,231,050
+208,579
+3% +$8.95M 0.04% 362
2020
Q2
$389M Buy
+8,022,471
New +$397M 0.05% 333

Other funds holding RPRX